


# The Effects of Sex Steroid Manipulation on Anhedonia In Women With and Without a History of Postpartum Depression



Danielle A. Swales<sup>1</sup>, Lauren Schiff<sup>2</sup>, David Rubinow<sup>1</sup>, & Crystal Edler Schiller<sup>1</sup>

<sup>1</sup>Department of Psychiatry, University of North Carolina at Chapel Hill; <sup>2</sup>Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill

## Background

- Sex steroid changes during the perinatal period can trigger depression in vulnerable women.
- Less work has explored whether pregnancy related hormone changes trigger anhedonia in women at risk for postpartum depression (PPD).
- Elucidating the biological underpinnings of anhedonia in PPD is important because women experiencing this symptom may feel less interested in things that would typically bring pleasure, including their infant.




# Objective


In the current study, we investigated the effects of experimentally controlled reproductive steroid exposure on anhedonia in women with a history of postpartum depression (PPD+) and those without such a history (PPD-).

## Method

 Participants included 23 healthy, euthymic, non-pregnant women with a history of PPD (PPD+; n = 11) and those with no history of PPD (PPD-; n = 12).









**Table 1. Descriptive statistics** 


Participant Characteristics	Descriptive Statistics
Age, in years ( $M \pm SD$ ; Range)	$35.3 \pm 5.3$ ; 22-43
Parity ( $M \pm SD$ ; Range)	$2.3 \pm 1.3; 1-5$
Race/Ethnicity (N; %)	
Asian	2; 8.7
Black or African American	1; 4.3
White	20; 87.0
Ethnicity (N; % Latinx/Hispanic)	3; 13.0
Household Income (N; %)	
<\$69,000	3; 13.0
\$70,000-\$99,999	6; 26.1
>\$100,000	14; 60.1
Years of education ( $M \pm SD$ ; Range)	$16.5 \pm 4.2; 0-20$

## **Study Design**

• The hormone states of pregnancy and parturition were simulated in the following study phases:

1. Hypogonadism	Administration of gonadotropin-releasing hormone (GnRH) agonist, leuprolide acetate (Lupron)
2. Addback	Supraphysiologic doses of estradiol (E2) and progesterone (P4)
3. Withdrawal	Withdrawal of E2 and P4

Figure 1. Overview of study design



#### Measures

- Inventory of Depression and Anxiety Symptoms (IDAS)
  - ➤ General Depression scale and Wellbeing scale (reverse scored)
- Behavioral Inhibition System and Behavioral Activation System (BIS/BAS) scales
  - > BIS, BAS Drive, BAS Fun Seeking, BAS Reward Response

## Results


• PPD+ and PPD- participants did not differ on general depression symptoms (t = -0.94, p = .360) or anhedonia measures at baseline (all p's > .250).

Table 2. Depression and anhedonia measures at baseline

Measure	M ± SD		_	<b>10</b>
	PPD+	PPD-	t	p
IDAS General Depression Scale	$34.1 \pm 5.6$	$31.7 \pm 5.6$	-0.94	.360
IDAS Wellbeing Scale (reverse scored)	$24.0 \pm 6.5$	$23.9 \pm 3.4$	-0.02	.988
BIS Scale	$21.0 \pm 3.1$	$21.6 \pm 2.2$	0.55	.591
BAS Drive Scale	$\textbf{10.7} \pm \textbf{1.8}$	$10.3\pm1.8$	-0.63	.533
BAS Fun Seeking Scale	$10.6 \pm 2.3$	$10.8 \pm 2.2$	0.14	.888
BAS Reward Response Scale	$17.1 \pm 1.5$	$17.0\pm1.6$	-0.17	.867


- Women with a history of PPD reported an increase in depression and anhedonia from baseline to hormone addback on the IDAS general depression scale (t = -2.3, p = .032), the IDAS reverse-coded wellbeing scale (t = -2.8, p = .011), and the BAS Drive scale (t = 2.4, p = .026).
- Anhedonia levels did not change from baseline to addback for control participants with no PPD history (all p's > .250).

Figure 2. Change in anhedonia scores from baseline to hormone addback for PPD+ and PPD- participants



## Discussion

- Findings support the role of sex steroids in perinatal-onset depression and suggest that sex-steroid changes can trigger anhedonia in susceptible women.
- Findings have important clinical implications, as the onset of anhedonia in the perinatal period can increase risk for postpartum depression and adversely impact the mother-infant relationship.



### Acknowledgements

This research was funded by NIMH R21 MH119615-01; Schiller, PI). D.A.S. receives support from the National Institute of Mental Health (T32 MH093315).